Coherus BioSciences, Inc. fell 22.6% on Thursday, October 29, 2026, on 6,132,000 shares, 4.2 times its average daily volume. Headlines around the move:
Coherus BioSciences, Inc. (CHRS:NASDAQ) closed at $0.797 on November 3, 2026, up 6.30% on the day. The stock trades 69.5% below its 52-week high of $2.62 and 6.8% above its 52-week low of $0.746. Over the past year, it lost 53.2%. Coherus BioSciences, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 31, 2025, CHRS closed higher on 116 days (46%). Its best day was January 23, 2026 (+29.56%) and its worst was October 29, 2026 (-22.59%). The stock moved 10% or more in a single session 13 times. It opened at least 5% above the previous day's high 2 times.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonsmall cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behcet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of...
Find more stocks like CHRS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.